Vertex Pharmaceuticals Financial Diagnostics

VRTX -- USA Stock  

USD 172.41  3.73  2.12%

The small decline in market price for the last few months may raise some interest from investors as it closed today at a share price of 171.13 on 854573.000 in trading volume. The company executives did not add much value to Vertex Pharmaceuticals investors in September. However, diversifying your holdings with Vertex Pharmaceuticals Incorpor or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.7694. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. This diagnostics interface makes it easy to digest most current publicly released information about Vertex Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Vertex Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency. Also please take a look at World Market Map.

Vertex Pharmaceuticals Note

About 97.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.79. Vertex Pharmaceuticals recorded earning per share (EPS) of 8.52. The entity had not issued any dividends in recent years. The firm had 2:1 split on 2000-08-24. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people. For more information please call Jeffrey Leiden at 617 341-6100 or visit www.vrtx.com.

Vertex Pharmaceuticals Alerts

Vertex Pharmaceuticals generates negative expected return over the last 30 days
Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Sale by Amit Sachdev of 1500 shares of Vertex Pharmaceuticals

Vertex Pharmaceuticals Upcoming and Recent Events

Upcoming Quarterly Earning ReportOctober 23, 2019
Next Earnings ReportFebruary 4, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndFebruary 4, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018

Vertex Pharmaceuticals Earning Estimates

EPSEstimate Date
Quarterly Estimate0.86October 23, 2019
Vertex Pharmaceuticals Incorpor normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Vertex Pharmaceuticals SEC Filings

Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Entry into a Material Definitive Agreement

Vertex Pharmaceuticals Thematic Classifications

Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 43.37 B.

Profitablity

The company has Profit Margin (PM) of 64.13 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 29.0 % which suggests for every 100 dollars of sales it generated a net operating income of 0.29.

Management Efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.

Stock Holders for Vertex Pharmaceuticals

Information
Ratio
Value
At Risk
Proshares UltraPro Nasdaq Biote(0.0412) (6.62) 
NASDAQ Developed Health Care Lg 0.0156 (2.28) 
NASDAQ N America Health Care Lg(0.07) (2.22) 
FormulaFolios US Equity Fund In(0.07) (1.52) 
Lord Abbett Health Care Fund - Class R3(0.10) (2.64) 
NQ US Pharma Biotech Lg Md C 0.0154 (1.66) 
American Century STOXX U S Qua(0.0143) (2.54) 
Invesco Dynamic Biotech Genom(0.07) (2.89) 
NQ US Biotech Large Mid Cap CA(0.1) (3.77) 
NASDAQ 100 Equal Weighted 0.0071 (3.08) 
NASDAQ 100 0.0136 (2.76) 
Dow Jones U S Biotechnology In 0.0136 (3.17) 
VanEck Vectors Biotech ETF(0.0396) (1.83) 
Nasdaq 100 Index CHF 0.09 (2.39) 
NASDAQ DM Ex Japan Large Mid Ca 0.00  0.00 
NASDAQ N America Health Care Lg(0.0262) (2.12) 
NQ US Biotech Large Mid Cap GB(0.014) (4.28) 
NASDAQ Developed Health Care Lg 0.0313 (1.98) 
NASDAQ DM Health Care Lg Md Cap(0.0107) (1.80) 
NASDAQ N America Health Care Lg 0.0165 (2.57) 

Technical Drivers

As of 16 of October Vertex Pharmaceuticals has Risk Adjusted Performance of 0.0114, Coefficient Of Variation of 13767.41 and Semi Deviation of 1.47. In relation to Fundamental Indicators, Macroaxis technical analysis interface makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals as well as the relationship between them. In other words you can use this information to find out if the company will indeed mirror its model of past prices and volume data or the prices will eventually revert. We found nineteen technical drivers for Vertex Pharmaceuticals Incorpor which can be compared to its competition. Please validate Vertex Pharmaceuticals Value At Risk as well as the relationship between Semi Variance and Kurtosis to decide if Vertex Pharmaceuticals is priced more or less accurately providing market reflects its prevalent price of 172.41 per share. Given that Vertex Pharmaceuticals has Jensen Alpha of 0.0206, we advise you double-check Vertex Pharmaceuticals Incorpor current market performance to make sure the company can sustain itself at future point.

Vertex Pharmaceuticals Price Movement Analysis

The output start index for this execution was eleven with a total number of output elements of fifty. The Weighted Moving Average calculates a weight for each value in Vertex Pharmaceuticals price series with the more recent values given greater weights. View also all equity analysis or get more info about weighted moving average overlap studies indicator.

Vertex Pharmaceuticals Insider Trading Activities

Amit Sachdev 2 days ago via Macroaxis 
Sale by Amit Sachdev of 1500 shares of Vertex Pharmaceuticals
Joshua Boger few days ago via Macroaxis 
Exercise or conversion by Joshua Boger of 4000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Connolly Thomas 1 few days ago via Macroaxis 
Sale by Connolly Thomas 1 of 5300 shares of Vertex Pharmaceuticals
Alam John J six days ago via Macroaxis 
Vertex Pharmaceuticals exotic insider transaction detected
Boger Kenneth S over a week ago via Macroaxis 
Exercise or conversion by Boger Kenneth S of 3160 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Joshua Boger over a week ago via Macroaxis 
Exercise or conversion by Joshua Boger of 11000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Brum Lynne H over a week ago via Macroaxis 
Exercise or conversion by Brum Lynne H of 1000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Sangeeta Bhatia over a week ago via Macroaxis 
Exercise or conversion by Sangeeta Bhatia of 5818 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Sangeeta Bhatia over a week ago via Macroaxis 
Sale by Sangeeta Bhatia of 5187 shares of Vertex Pharmaceuticals
Joshua Boger over two weeks ago via Macroaxis 
Sale by Joshua Boger of 2969 shares of Vertex Pharmaceuticals
Graves Kurt over two weeks ago via Macroaxis 
Sale by Graves Kurt of 925 shares of Vertex Pharmaceuticals
Brandt Eric over two weeks ago via Macroaxis 
Acquisition by Brandt Eric of 10000 shares of Vertex Pharmaceuticals subject to Rule 16b-3

Vertex Pharmaceuticals Technical and Predictive Indicators

Vertex Pharmaceuticals Forecast Models

Recommendations

Vertex Pharmaceuticals Analyst Recommendations

Target PriceAdvice# of Analysts
214.08Buy13Odds
Vertex Pharmaceuticals Incorpor current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Vertex Pharmaceuticals Analyst Advice  

Vital Value Indicators

Vertex Pharmaceuticals Basic Pricing Drivers

Quick Ratio3.51
Fifty Two Week Low151.80
Revenue Growth25.10%
Shares Short Prior Month3.87M
Average Daily Volume Last 10 Day1.1M
Average Daily Volume In Three Month1.17M
Earnings Growth28.50%
Shares Percent Shares Out1.64%
Gross Margins43.51%
Earnings Quarterly Growth29.00%
Short Percent Of Float1.83%
Forward Price Earnings27.30
Float Shares256.66M
Fifty Two Week High195.81
Enterprise Value To Ebitda40.21
Fifty Day Average175.44
Two Hundred Day Average175.94
Enterprise Value To Revenue11.66
Also please take a look at World Market Map. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.
Search macroaxis.com